|
1
|
Maroun G, Fissoun C, Villaverde M, Brondello JM, Pers YM. Senescence-regulatory factors as novel circulating biomarkers and therapeutic targets in regenerative medicine for osteoarthritis. Joint Bone Spine 2024; 91:105640. [PMID: 37739212 DOI: 10.1016/j.jbspin.2023.105640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 09/07/2023] [Accepted: 09/12/2023] [Indexed: 09/24/2023]
Abstract
Recent discoveries reveal that the chronic presence of senescent cells in osteoarticular tissues provides a focal point of disease development for osteoarthritis (OA). Nevertheless, senescence-regulatory factors associated with OA still need to be identified. Furthermore, few diagnostic- and prognostic-validated biochemical markers (biomarkers) are currently used in clinics to evaluate OA patients. In the future, alongside imaging and clinical examination, detecting senescence-regulatory biomarkers in patient fluids could become a prospective method for disease: diagnosis, monitoring, progression and prognosis following treatment. This review summarizes a group of circulating OA biomarkers recently linked to senescence onset. Remarkably, these factors identified in proteomics, metabolomic and microRNA studies could also have deleterious or protective roles in osteoarticular tissue homeostasis. In addition, we discuss their potentially innovative modulation in combination with senotherapeutic approaches, for long-lasting OA treatment.
Collapse
Affiliation(s)
- Georges Maroun
- Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM UMR 1183, 34298 Montpellier, France
| | - Christina Fissoun
- Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM UMR 1183, 34298 Montpellier, France
| | - Marina Villaverde
- Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM UMR 1183, 34298 Montpellier, France; HCS Pharma, Biocentre Fleming, 250, rue Salvador-Allende, Bat A, 59120 Loos, France
| | - Jean-Marc Brondello
- Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM UMR 1183, 34298 Montpellier, France
| | - Yves-Marie Pers
- Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM UMR 1183, 34298 Montpellier, France; Clinical immunology and osteoarticular diseases Therapeutic Unit, Lapeyronie University Hospital, CHU Montpellier, IRMB, University of Montpellier, INSERM, Montpellier, France.
| |
Collapse
|
|
2
|
Inglés-Ferrándiz M, Martin-Inaraja M, Herrera L, Villaverde M, Santos S, Vesga MA, Garreta E, Martín-Ruiz I, Aransay AM, Anguita J, Barreña B, Allende LM, Gonzalez-Granado LI, Eguizabal C. Generation, establishment and characterization of a pluripotent stem cell line (CVTTHi001-A) from primary fibroblasts isolated from a patient with activated PI3 kinase delta syndrome (APDS2). Stem Cell Res 2020; 49:102082. [PMID: 33221676 DOI: 10.1016/j.scr.2020.102082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 11/01/2020] [Indexed: 11/27/2022] Open
Abstract
APDS2 is caused by mutations in PIK3R1 gene resulting in constitutive PI3Kδ activation. PI3Kδ is predominantly expressed in leukocytes and plays critical roles in regulating immune responses. Here we first derived fibroblast primary cells from a skin biopsy of a patient carrying a heterozygous single T deletion in intron 11 of the PIK3R1 gene. We next present the derivation of an induced pluripotent stem cell (iPS) line using a non-integrative reprogramming technology. Pluripotent-related hallmarks are further shown, including: iPSCs self-renewal and expression of pluripotent and differentiation markers after in vitro differentiation towards embryonic germ layers, assessed by RT-PCR and immunofluorescence.
Collapse
Affiliation(s)
- M Inglés-Ferrándiz
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
| | - M Martin-Inaraja
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
| | - L Herrera
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
| | - M Villaverde
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
| | - S Santos
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
| | - M A Vesga
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
| | - E Garreta
- Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain. University of Barcelona, Barcelona, Spain
| | - I Martín-Ruiz
- Inflammation and Macrophage Plasticity Laboratory, CIC bioGUNE-BRTA (Basque Research and Technology Alliance), Derio 48160, Spain
| | - A M Aransay
- Genomic Analysis Platform, CIC bioGUNE-BRTA, Derio, 48160, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - J Anguita
- Inflammation and Macrophage Plasticity Laboratory, CIC bioGUNE-BRTA (Basque Research and Technology Alliance), Derio 48160, Spain; Ikerbasque, Basque Foundation for Science, Bilbao 48013, Spain
| | - B Barreña
- Genetics Unit, Hospital de Basurto, Bilbao, Spain
| | - L M Allende
- Immunology Department, University Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), School of Medicine, University Hospital 12 de Octubre, Complutense University of Madrid, Madrid, Spain
| | - L I Gonzalez-Granado
- Primary Immunodeficiencies Unit, Pediatrics, Hospital 12 Octubre (imas12), Complutense University School of Medicine, Madrid, Spain
| | - C Eguizabal
- Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.
| |
Collapse
|
|
3
|
Malhotra R, Usyvat L, Raimann J, Thijssen S, Levin N, Kotanko P, Hilderman M, Qureshi AR, Al-Abed Y, Anderstam B, Bruchfeld A, Minco M, Argentino G, Grumetto L, Postiglione L, Memoli B, Riccio E, Striker G, Yubero-Serrano E, Uribarri J, Vlassara H, do Sameiro-Faria M, Ribeiro S, Kohlova M, Rocha-Pereira P, Fernandes J, Nascimento H, Reis F, Miranda V, Bronze-da-Rocha E, Quintanilha A, Costa E, Belo L, Santos-Silva A, Modilca M, Margineanu M, Gluhovschi G, Vernic C, Velciov S, Petrica L, Barzuca E, Gluhovschi C, Balgradean C, Kaycsa A, Stockler-Pinto M, Dornelles S, Cozzolino S, Malm O, Mafra D, Cobo G, Rodriguez I, Oliet A, Hinostroza J, Vigil A, Di Gioia M, Gallar P, Drechsler C, Wanner C, Blouin K, Pilz S, Tomaschitz A, Krane V, Marz W, Ritz E, van der Harst P, de Boer R, Carrero JJ, Cabezas-Rodriguez I, Zoccali C, Qureshi A, Ketteler M, Gorriz J, Rutkowski B, Teplan V, Kramar R, Pavlovic D, Goldsmith D, Benedik M, Fernandez-Martin J, Cannata-Andia J, Guido G, Loiacono E, Serriello I, Camilla R, Coppo R, Amore A, Schiller A, Munteanu M, Schiller O, Mihaescu A, Olariu N, Andrei C, Anton C, Ivacson Z, Roman V, Berca S, Bansal V, Marcelli D, Grassmann A, Bayh I, Scatizzi L, Marelli C, Etter M, Usvyat L, Kooman J, Sande F, Levin N, Kotanko P, Canaud B, Quiroga B, Villaverde M, Abad S, Vega A, Reque J, Yuste C, Barraca D, Perez de Jose A, Lopez-Gomez JM, Castellano Gasch S, Palomares I, Dominguez J, Ramos R, Schmidt J, Hafer C, Clajus C, Hadem J, Schmidt B, Haller H, Kielstein J, Katagiri M, Kamada Y, Kobayashi N, Moriguchi I, Ito Y, Kamekawa D, Akiyama A, Ishii H, Tanaka S, Kamiya K, Hamazaki N, Kato M, Shimizu R, Hotta K, Masuda T, Veronesi M, Mancini E, Valente F, Righetti F, Brunori G, Santoro A, Bal Z, Tutal E, Erkmen Uyar M, Guliyev O, Sayin B, Sezer S, Mikami S, Hamano T, Tanaka T, Iba O, Toki M, Mikami H, Takamitsu Y, Inoue T, Fujii M, Hirayama A, Ueda A, Watanabe R, Matsui H, Nagano Y, Nagase S, Aoyagi K, Owada S, Tutal E, Bal Z, Erkmen Uyar M, Sayin B, Tot U, Sezer S, Onec K, Erten Y, Pasaoglu O, Ebinc F, Uludag K, Okyay G, Inal S, Pasaoglu H, Deger S, Arinsoy T, Arias-Guillen M, Masso E, Perez E, Herrera P, Romano B, Perez N, Maduell F, Jung YS, Kim YN, Shin HS, Rim H, Al Ismaili Z, Hassan M, Dastoor H, Bernieh B, Ismael A, Marcelli D, Richards N, Khil M, Sheiman B, Dudar I, Gonchar Y, Khil V, Kim HL, Ryu HH, Kim SH, Bosch Benitez-Parodi E, Baamonde Laborda E, Perez Suarez G, Ramirez JI, Garcia Canton C, Guerra R, Ramirez Puga A, Toledo A, Lago Alonso MM, Checa Andres MD, Hwang WM, Yun SR, Molsted S, Andersen JL, Eidemak I, Harrison AP, Kose E, Turgutalp K, Kiykim A, Celik F, Gok Oguz E. Protein-energy wasting. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|